Westlake Aging Cohort: following 55+ to map aging and cognitive changes
Official title: Westlake Aging Cohort
Run by Westlake University · NCT07373444 · Data updated 2026-11-12
A large observational study in Hangzhou will follow 2,800 adults aged 55–90 to see how aging, cognition, and neurodegenerative diseases relate to biology over time.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 55 Years to 90 Years |
| Sex | All |
| Enrollment | 2800 (estimated) |
| Sponsor | Westlake University Academic / other |
| Locations | 2 sites (Hangzhou, Zhejiang and 1 other locations) |
| Status | Recruiting |
| Started | June 3, 2026 |
| Main results expected | December 31, 2030 |
| Study ends | December 31, 2031 |
| Registry record updated | November 6, 2026 |
| Trial ID | NCT07373444 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 55–90 in Hangzhou, including healthy controls and those with MCI, AD, PDD, or DLB, with a willing companion and ability to complete regular assessments.
✕Probably not a fit
Patients unlikely to benefit are those outside the age range, unable to participate in long-term follow-up, or lacking a capable companion for assessments.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational cohort will collect demographic, lifestyle, clinical, neuroimaging, and multi-omics data from healthy individuals and patients with MCI, AD, PDD, and DLB to build a longitudinal database. The study aims to identify molecular signatures and biomarkers linked to neurodegenerative progression and to understand mechanisms behind cognitive decline. Data will come from repeated surveys, exams, imaging, and biological samples, enabling analyses of trajectories and potential risk factors. The project is centered in Hangzhou and leverages collaboration between Westlake University and local hospitals. It does not specify an intervention; the value lies in rich, multi-omics, longitudinal characterization.
Why it matters
Potential benefit: If successful, the study could reveal biomarkers and pathways that predict cognitive decline and support early intervention strategies.
How similar studies have gone: Similar longitudinal cohorts in aging and cognition have provided valuable biomarkers and progression insights, though this study’s multi-omics integration is relatively advanced.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age between 55 and 90 years (inclusive) at baseline. 2. Availability of a companion capable of providing independent functional assessments and fluent in Chinese. 3. Willingness and ability to regularly complete required surveys and physical examinations as per study protocol. 4. MMSE scores were required to be 24-30 (inclusive) for healthy controls and MCI; and 20-24 (inclusive) for AD and DLB/PDD patients. 5. Healthy controls: CDR = 0, memory box = 0. MCI: CDR = 0.5, memory box ≥ 0.5. AD: CDR = 0.5 or 1. The DLB/PDD meets the core features of diagnosis. 6. Healthy controls exhibit no significant cognitive or functional decline. Patients with MCI have objective cognitive impairment not sufficient for an AD diagnosis. AD patients fulfill the NINCDS-ADRDA criteria. DLB/PDD patients meet their respective international consensus diagnostic criteria. Other neurodegenerative diseases meet the diagnostic criteria. Exclusion Criteria: 1. Participants with major medical or neuropsychiatric conditions unrelated to the study purposes were excluded. These included, but were not limited to, psychiatric disorders, cancer, infectious diseases, structural brain abnormalities, and epilepsy. 2. Current use of psychoactive medications or any other drugs that may affect the study. 3. Participants with cardiac pacemakers, artificial heart valves, or metallic implants in the eyes, skin, or any other part of the body. 4. Participants with any other diseases that may affect the study.
Where it's running
-
Hangzhou First People's Hospital
Hangzhou, Zhejiang, China Recruiting -
Hangzhou Third People's Hospital
Hangzhou, Zhejiang, China Recruiting
Study contacts
- Principal investigator: Ju-Sheng Zheng, PhD — Westlake University
- Study coordinator: Ju-Sheng Zheng, PhD
- Email: zhengjusheng@westlake.edu.cn
- Phone: 86-0571-86915303
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Norms for a Voice-Based Digital Cognitive Test Across Ages
This study tests a voice-enabled digital cognitive test to establish normal scores for adults aged 18–100.
-
Cognitive Vitality Pilot: 45-day supplement for thinking and mood
This study will test whether taking the liquid supplement Axolt daily for 45 days helps thinking and mood in healthy adults aged 55 and older.
-
Using robots to help older adults become more physically active
This study is testing whether using robots can help older adults become more active by changing their automatic thoughts about physical activity.
-
Examining the link between sleep and cognitive performance in older adults
This study is testing how different aspects of sleep affect memory and thinking skills in older adults using a wearable device to track their sleep.
-
Observational study on Alzheimer's disease and cognitive health in older adults
This study is looking for older adults with and without memory problems to help researchers learn more about Alzheimer's disease and improve ways to prevent and treat it.
-
A study on brain health and aging in Bordeaux.
This study is trying to understand how different factors, like diet and health, affect brain aging and the risk of dementia in people aged 55 and older living in Bordeaux.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.